 The FDA has issued a Complete Response Letter CRL regarding Verrica Pharmaceuticals Incs NASDAQ: VRCA marketing application seeking approval for VP-102 for molluscum contagiosum, a highly contagious viral skin disease. The FDA had previously extended the Prescription Drug User Fee Act PDUFA goal date for the application by three months. 